Stockscreener 앱 받기
7.32
6.09%
0.42
전일 마감가:
$6.90
열려 있는:
$7.8
하루 거래량:
783
Relative Volume:
0.20
시가총액:
$N/A
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-38.80%
1개월 성능:
-30.94%
6개월 성능:
-3.05%
1년 성능:
-28.59%
1일 변동 폭
$7.19
$7.83
1주일 범위
$6.90
$12.24
52주 변동 폭
$5.52
$16.75
Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile
명칭
Newamsterdam Pharma Company N V
전화
31 35 206 2971
주소
Gooimeer 2-35, Naarden
NAMSW을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAMSW
Newamsterdam Pharma Company N V
|
7.32 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Newamsterdam Pharma Company N V 주식(NAMSW)의 최신 뉴스
American Century Companies Inc. Acquires Shares of 346,572 NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Teacher Retirement System of Texas Makes New $276,000 Investment in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Leading Cardiovascular Drug Developer NewAmsterdam Sets Key Investor Presentation - Stock Titan
Newamsterdam Pharma CEO Michael Davidson sells shares for $281,000 By Investing.com - Investing.com Australia
Newamsterdam Pharma director James Topper buys $25,520 in shares By Investing.com - Investing.com Australia
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Swiss National Bank - Defense World
Newamsterdam pharma COO sells shares worth $376,000 By Investing.com - Investing.com Canada
Newamsterdam Pharma CEO Michael Davidson sells shares for $281,000 - Investing.com India
Newamsterdam pharma COO sells shares worth $376,000 - Investing.com India
Newamsterdam Pharma director James Topper buys $25,520 in shares - Investing.com
Newamsterdam Pharma COO Kling sells $2.36 million in stock By Investing.com - Investing.com Australia
Newamsterdam Pharma COO Kling sells $2.36 million in stock - Investing.com
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by US Bancorp DE - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Receives $43.33 Consensus Price Target from Analysts - Defense World
Financial Metrics Exploration: Understanding NewAmsterdam Pharma Company NV (NAMS) Through Ratios - The Dwinnex
9,983 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by Keybank National Association OH - Defense World
A better buy-in window may exist right now for NewAmsterdam Pharma Company NV (NAMS) - SETE News
Newamsterdam pharma director James Topper buys $84,203 in shares By Investing.com - Investing.com Australia
Newamsterdam pharma director James Topper buys $84,203 in shares - Investing.com
New Amsterdam Pharma chief accounting officer sells $3.06 million in shares - Investing.com India
New Amsterdam Pharma chief accounting officer sells $3.06 million in shares By Investing.com - Investing.com South Africa
William Blair Has Negative Forecast for NAMS Q1 Earnings - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Price Target Raised to $52.00 - Defense World
(NAMS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib - Seeking Alpha
NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution (NASDAQ:NAMS) - Seeking Alpha
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? - AOL
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Yearly Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
NewAmsterdam Pharma’s 2024 Financial Results and Clinical Progress - TipRanks
7 Analysts Have This To Say About NewAmsterdam Pharma - Benzinga
Scotiabank raises NewAmsterdam Pharma target to $52 - Investing.com India
Scotiabank raises NewAmsterdam Pharma target to $52 By Investing.com - Investing.com South Africa
Newamsterdam Pharma Faces Potential Investor Risks Due to Shareholder Influence - TipRanks
NewAmsterdam Pharma's Full-Year Net Loss Widens, Revenue Rises -February 26, 2025 at 08:27 am EST - Marketscreener.com
Earnings Flash (NAMS) NewAmsterdam Pharma Posts Full Year 2024 Revenue $45.6M, vs. FactSet Est of $33.8M - Marketscreener.com
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
NewAmsterdam Pharma Co N.V. SEC 10-K Report - TradingView
Can NewAmsterdam's Obicetrapib Reshape Cardiovascular Treatment? Phase 3 Results Show 49% LDL-C Reduction - StockTitan
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - The Manila Times
NewAmsterdam Pharma Company N.V. (NAMS): Among the Oversold Biotech Stocks to Buy Now - Insider Monkey
Newamsterdam Pharma Company N V (NAMSW) 재무 분석
Newamsterdam Pharma Company N V (NAMSW)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):